Competition heats up in domestic allergic rhinitis market

Competition in the local allergic rhinitis market is heating up because generic manufacturers are increasing efforts to occupy the runner-up slot by deploying aggressive marketing strategies.

The domestic allergic rhinitis market is valued at 200 billion won, which is predominated by Merck’s Singulair (montelukast sodium).

Montelukast sodium is a leukotriene receptor antagonist used for t...